Interview 10 Aug 2022 How the UK precision breeding bill could unshackle gene editing The U.K. is considering lowering restrictions on gene-edited crops. PacBio’s Neil Ward explains how the changes could impact the gene editing landscape. CRISPR gene editing technology has changed the game in the biotech industry by making it easier than ever before to make small changes to the genome. In addition to myriad healthcare applications, the […] August 10, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 21 Jul 2022 Finding investment opportunities in a bleak biotech stock market The situation remains difficult in public markets as biotech stocks struggle to recover from a 50% decline over the past year. However, the venture capital (VC) firm Sofinnova Partners is no stranger to downturns, and partner Joe Anderson explains how the industry is shifting in favor of life sciences investors. It’s a tough time to […] July 21, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 12 Jul 2022 Where AI can’t go: PhoreMost’s quest to unearth protein degradation targets Advances in the AI-powered simulation of proteins are making it easier than ever to discover new drugs. Neil Torbett, CEO of PhoreMost, outlines how the firm’s protein screening technology overcomes current limitations of protein structure predictions, with big applications in the emerging field of protein degradation. Proteins are a critical component to a cell’s activities, […] July 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 10 Jan 2022 Leveraging Physics and Quantum Computing to Accelerate Drug Discovery Novel computational techniques are revolutionizing the way we discover new drugs. Robert Marino, CEO and co-founder of Qubit Pharmaceuticals, discusses the potential of physics to accelerate drug discovery. Paris-based Qubit Pharmaceuticals was established in 2020 to commercialize the work of leading researchers in the computational chemistry space. This field uses computer modeling to predict how […] January 10, 2022 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 13 Oct 2021 Thinking About Risk Early on Is Key for Cell Therapy Success For cell therapy to become mainstream, important issues such as management of risk and quality control need to be addressed, argues Duncan Borthwick, Global Marketing Manager at cell therapy manufacturing firm Solentim. Research and development of cell therapies, along with other advanced medicines like gene therapies, has increased exponentially over the last few years. According […] October 13, 2021 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 23 Aug 2021 Behind the Scenes at Novo Seeds: Building Startups from the Ground up Søren Møller, Managing Investment Director at Novo Seeds, discusses how the firm’s investment strategy has changed over time to support the creation of biotech startups in the Nordics. Søren Møller has a PhD in molecular biology from the Technical University of Denmark. After spending some time as a postdoc at Stanford University in the US […] August 23, 2021 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 31 May 2021 What’s Ahead for European Biotech Startups After Covid? With a tumultuous year behind us, 2021 is set out to spell change for many startups in the European biotech ecosystem. Following the Covid-19 pandemic and Brexit, the European biotech startup landscape has seen some big changes over the course of the past year. Jason Mellad and Dan Rooke, CEO and COO of the Cambridge-based […] May 31, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Interview 26 May 2021 Immuno-Oncology: From Science Fiction to the Mainstream In just a couple of decades, immuno-oncology has taken center stage in the biotechnology industry. We discuss the evolution of the field with experts who have been in it from the very beginning. While immuno-oncology is one of the hottest areas of medicine at the moment, that wasn’t the case 20 years ago. The idea […] May 26, 2021 - 7 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 19 May 2021 Are Biotech Startups Ready for Augmented Reality? Augmented reality is starting to become a part of the manufacturing process of pharma and biotech companies. Paul Haimes, Vice President of Engineering at PTC, discusses the benefits and challenges to implementing this technology across the biotech industry. Augmented reality (AR) is increasingly being used to maintain and optimize biomanufacturing processes, which can bring economic […] May 19, 2021 - 8 minutesmins - By Carlos de Rojas Share WhatsApp Twitter Linkedin Email
Interview 10 May 2021 The Rollercoaster of Repurposing an Arthritis Drug for Covid-19 The Covid-19 pandemic created an opportunity for many biotech companies to repurpose their existing programs into vaccines and treatments for the novel coronavirus. Cyxone’s CEO Tara Heitner and COO Malin Berthold discuss how they approached this shift at their company. Cyxone was founded in 2015 to develop drugs for rheumatoid arthritis and multiple sclerosis. Based […] May 10, 2021 - 8 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email
Interview 21 Apr 2021 Changing Attitudes on Vaccine and Public Health Investment The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. Rockman did not plan to get into life science investment. With a […] April 21, 2021 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 5 Apr 2021 Base Editing: The Next Frontier in Genome Editing Technology Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […] April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin Share WhatsApp Twitter Linkedin Email